Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Epoetin Beta in Treating Anemia in Patients With Cervical Cancer

Phase 4

Completed

Conditions: Anemia
Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-30

Lead Sponsor: AGO Study Group

Target Recruit Count: 450

Registration Number: NCT00046969

Locations: 🇩🇪
Martin Luther Universitaet, Halle, Germany

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

Phase 1

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 40

Registration Number: NCT00003379

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 28 locations

Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Phase 3

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 400

Registration Number: NCT00003945

Locations: 🇺🇸
Mercy Cancer Center at Mercy Medical Center-Des Moines, Des Moines, Iowa, United States
🇺🇸
John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 8 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: isotretinoin
Drug: melphalan
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support
Procedure: conventional surgery
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 495

Registration Number: NCT00004188

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 93 locations

Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

Phase 2

Terminated

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00033644

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Tuft-New England Medical Center, Boston, Massachusetts, United States

and more 18 locations

S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-10

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 78

Registration Number: NCT00006248

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

and more 92 locations

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 3

Completed

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Drug: etoposide
Drug: gefitinib
Radiation: radiation therapy
Other: placebo

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 840

Registration Number: NCT00020709

Locations: 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States

S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 33

Registration Number: NCT00014196

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States

and more 94 locations

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Lymphoma
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: filgrastim
Drug: becatecarin
Drug: cisplatin

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00004189

Locations: 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸
St. Luke's Lutheran Hospital, San Antonio, Texas, United States

Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus

Phase 3

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-23

Lead Sponsor: UNICANCER

Target Recruit Count: 250

Registration Number: NCT00002883

Locations: 🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy